Noticias y vídeos - XTANT MEDICAL HLD. - Página 2

BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Irix-C cervical cage for use with autograft and/or allograft and the expansion of the range of levels allowable from C3-T1 to C2-T1. Previously the device was cleared only for use with autogenous bone graft. This furthers Xtant Medical's...

BELGRADE, Mont., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical cases of the Xspan Laminoplasty Fixation System. The first two cases were performed by Dr. Francisco Vaz-Guimaraes at the Michael E. DeBakey VA Medical Center in Houston. The open door laminoplasty procedure was performed to treat spinal stenosis without fusing the vertebrae. "The...

BELGRADE, Mont., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, reminds rights holders that the subscription period for its previously announced rights offering expires at 5:00 PM Eastern Time on Monday, November 14, 2016. The rights offering is for up to 15,000,000 units, each consisting of one share of common stock and one warrant to purchase...

BELGRADE, Mont., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has adjusted the subscription price and related pricing information for its previously announced rights offering of up to 15,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The subscription...

*See footnote about the use of pro forma financial information Third Quarter 2016 Highlights: Company revenue increased 10.5% to $23.1 million, as compared to pro forma revenue of $20.9 million in third quarter 2015 Gross profit increased to $16.0 million, as compared to pro forma third quarter 2015 gross profit of $13.7 million Gross margins expanded to 69.2%, compared to 65.5% for the pro forma third quarter of 2015 The Company reported net loss of $4.9 million for the third quarter 2016,...

BELGRADE, Mont., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that the NYSE MKT LLC (the "Exchange") notified the Company that it accepted the Company's plan to regain compliance with the continued listing requirements of the Exchange. On August 19, 2016, the Company received notice that they are not in compliance with NYSE MKT...

BELGRADE, Mont., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has commenced the subscription period for its previously announced rights offering of up to 15,000,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The rights offering will remain open until 5:00...

BELGRADE, Mont., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, provides stockholders and convertible note holders a reminder of the Company’s previously announced rights offering and related key dates, as institutional and individual investors who wish to participate in the rights offering should ensure they own Xtant Medical’s common stock...

BELGRADE, Mont., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended September 30, 2016, at the close of the financial markets on Monday, November 7, 2016. An accompanying conference call will be hosted by Dan Goldberger, Chief Executive Officer, and John Gandolfo, Chief Financial Officer, to discuss the...

*See footnote about the use of pro forma financial information Record Third Quarter 2016 Revenue in the range of $23.0 million to $23.3 million Third Quarter 2016 Revenue represents an increase of 10.0% to 11.5% compared to pro forma Third Quarter 2015 Revenue of $20.9 million and a sequential increase of 7.2% to 8.6% compared to Second Quarter 2016 revenue BELGRADE, Mont., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative...

BELGRADE, Mont., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today provided an informational update to stockholders and convertible note holders regarding its planned rights offering and the key dates relative to the offering. Institutional and individual investors who wish to participate in the rights offering should ensure they own the...

BELGRADE, Mont., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as President, reporting to the CEO effective October 6, 2016. Mr. O’Connell will lead all commercial efforts by providing the vision, leadership, strategy and management skills necessary to continue and further develop Xtant Medical’s successful commercial...